NCT03749317View on ClinicalTrials.gov

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

December 31, 2024

Conditions
Adenoviral Conjunctivitis
Interventions
DRUG

IVIEW-1201

IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days

DRUG

Placebo

Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days

Trial Locations (1)

700120

Disha Eye Hospital, Kolkata

Sponsors
All Listed Sponsors
lead

IVIEW Therapeutics Inc.

INDUSTRY

NCT03749317 - Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis | Biotech Hunter | Biotech Hunter